ResearcherFourth Hospital of Hebei MedicalActive in the last 2 years

Li Peng

Provisional: name at one institution (moderate confidence)As of 14 November 2026

Known by name at one institution; no external author ID yet. Name as it appears in ClinicalTrials.gov.

Their work

Counts cover pancreatic cancer work only: a researcher’s other papers, trials and grants are not in these records.

Pancreatic cancer papers: 0
Pancreatic cancer trials: 1 (principal investigator on 1)
Pancreatic cancer grants: 0
Collaborators: 1

Papers, trials and grants by year

2024: 1 trial

Trials 1

Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer Principal investigator NCT06435260 ↗

Closest collaborators

The 1 strongest of 1 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Fengpeng Wu · 1 shared trial, 2024
- Trial Hypofractionated Radiotherapy +Chemotherapy+ Camrelizumab as Neoadjuvant Therapy for Pancreatic Cancer NCT06435260 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.